Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in CANADA

Lead Product(s): Tirofiban Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Hong Kong Teson Pharma

Deal Size: $3.5 million Upfront Cash: $3.0 million

Deal Type: Agreement March 10, 2020

Details:

The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.

Lead Product(s): Cannabidiol

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Health Canada

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 15, 2020

Details:

Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.